BIO
Price
$245.37
Change
+$5.37 (+2.24%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
9.79B
21 days until earnings call
COO
Price
$81.21
Change
-$0.06 (-0.07%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
19.72B
56 days until earnings call
Ad is loading...

BIO vs COO

Header iconBIO vs COO Comparison
Open Charts BIO vs COOBanner chart's image
Bio-Rad Laboratories
Price$245.37
Change+$5.37 (+2.24%)
Volume$424
Capitalization9.79B
Cooper Companies (The)
Price$81.21
Change-$0.06 (-0.07%)
Volume$69.37K
Capitalization19.72B
BIO vs COO Comparison Chart
Loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIO vs. COO commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and COO is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (BIO: $245.52 vs. COO: $81.27)
Brand notoriety: BIO and COO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIO: 74% vs. COO: 104%
Market capitalization -- BIO: $9.79B vs. COO: $19.72B
BIO [@Medical Specialties] is valued at $9.79B. COO’s [@Medical Specialties] market capitalization is $19.72B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 0 FA rating(s) are green whileCOO’s FA Score has 0 green FA rating(s).

  • BIO’s FA Score: 0 green, 5 red.
  • COO’s FA Score: 0 green, 5 red.
According to our system of comparison, both BIO and COO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 4 TA indicator(s) are bullish while COO’s TA Score has 5 bullish TA indicator(s).

  • BIO’s TA Score: 4 bullish, 4 bearish.
  • COO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, COO is a better buy in the short-term than BIO.

Price Growth

BIO (@Medical Specialties) experienced а +0.08% price change this week, while COO (@Medical Specialties) price change was -2.90% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.75%. For the same industry, the average monthly price growth was +3.84%, and the average quarterly price growth was +3.01%.

Reported Earning Dates

BIO is expected to report earnings on Apr 24, 2025.

COO is expected to report earnings on May 29, 2025.

Industries' Descriptions

@Medical Specialties (-1.75% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COO($19.7B) has a higher market cap than BIO($9.79B). COO has higher P/E ratio than BIO: COO (68.09) vs BIO (3.64). COO YTD gains are higher at: -11.596 vs. BIO (-25.263). COO has higher annual earnings (EBITDA): 895M vs. BIO (-654.76M). BIO has more cash in the bank: 1.61B vs. COO (135M). BIO has less debt than COO: BIO (1.41B) vs COO (2.77B). COO has higher revenues than BIO: COO (3.67B) vs BIO (2.67B).
BIOCOOBIO / COO
Capitalization9.79B19.7B50%
EBITDA-654.76M895M-73%
Gain YTD-25.263-11.596218%
P/E Ratio3.6468.095%
Revenue2.67B3.67B73%
Total Cash1.61B135M1,190%
Total Debt1.41B2.77B51%
FUNDAMENTALS RATINGS
BIO vs COO: Fundamental Ratings
BIO
COO
OUTLOOK RATING
1..100
2010
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9583
PRICE GROWTH RATING
1..100
6462
P/E GROWTH RATING
1..100
8090
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COO's Valuation (77) in the Medical Specialties industry is in the same range as BIO (79). This means that COO’s stock grew similarly to BIO’s over the last 12 months.

COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that COO’s stock grew similarly to BIO’s over the last 12 months.

COO's SMR Rating (83) in the Medical Specialties industry is in the same range as BIO (95). This means that COO’s stock grew similarly to BIO’s over the last 12 months.

COO's Price Growth Rating (62) in the Medical Specialties industry is in the same range as BIO (64). This means that COO’s stock grew similarly to BIO’s over the last 12 months.

BIO's P/E Growth Rating (80) in the Medical Specialties industry is in the same range as COO (90). This means that BIO’s stock grew similarly to COO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOCOO
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
51%
Momentum
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 13 days ago
69%
Bullish Trend 7 days ago
62%
Declines
ODDS (%)
Bearish Trend 8 days ago
65%
Bearish Trend 21 days ago
55%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
57%
View a ticker or compare two or three
Ad is loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UCIB27.240.63
+2.38%
UBS ETRACS BgCstMtCdy(CMCI)TtlRetETNSerB
UDEC34.490.18
+0.52%
Innovator U.S. Equity Ultra BffrETF™-Dec
JAAA50.530.01
+0.02%
Janus Henderson AAA CLO ETF
PHDG36.40-0.06
-0.16%
Invesco S&P 500® Downside Hedged ETF
BAR30.78-0.06
-0.19%
GraniteShares Gold Trust